Promises from trametinib in RAF active tumors

New England Journal of Medicine

Volumn 367, Issue 2, 2012, Pages 171-172

  Sausville, Edward A ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYTOTOXIC AGENT; ERLOTINIB; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; TRAMETINIB; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CARCINOGENESIS; EDITORIAL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MUTATIONAL ANALYSIS; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84863698669     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1205654     Document Type: Editorial

References (10)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
2. Laurent-Puig P, Lievre A, Blons H. Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res 2009;15:1133-9.
3. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2011;9:16-32.
4. Wang D, Boerner SA, Winkler JD, LoRusso PM. Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta 2007;1773:1248-55.
5. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54. (Pubitemid 34716871)
6. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
7. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14.
8. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
9. Gilmartin AG, Bleam MR, Grov A, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011;17:989-1000.
10. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity. Nature 2012;483:603-7.